secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aprea Therapeutics, Inc. (APRE)
CIK:        0001781983
Form:       8-K
Filed at:   2026-03-16T23:59:59+00:00
Accession:  0001104659-26-028046
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aprea Therapeutics reports FY2025 net loss of $12.6M; APR-1051 shows two partial responses
--------------------------------------------------------------------------------

- Cash and equivalents $14.6M at Dec 31, 2025; plus Jan 2026 private placement of $5.6M funds operations into Q1 2027.
- Net loss $12.6M ($1.93/share) for FY2025 vs $13.0M ($2.35/share) in FY2024; R&D spend down to $7.0M from $9.4M.
- APR-1051 (WEE1 inhibitor) yields two unconfirmed partial responses in PPP2R1A-mutated endometrial cancer; dose escalation ongoing at 220 mg.
- ATRN-119 (ATR inhibitor) RP2D set at 1,100 mg; monotherapy enrollment paused, exploring combination studies.
- Appointed Eugene Kennedy, MD, as Chief Medical Advisor in February 2026 to support next phase of development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1781983/000110465926028046/0001104659-26-028046-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1781983/000110465926028046/apre-20260316x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-028046

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer